Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

The clinical profile of NMOSD in Australia and New Zealand.

Bukhari W, Clarke L, O'Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA.

J Neurol. 2020 Jan 31. doi: 10.1007/s00415-020-09716-4. [Epub ahead of print]

PMID:
32006158
2.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T.

Mult Scler Relat Disord. 2019 Nov 25;38:101868. doi: 10.1016/j.msard.2019.101868. [Epub ahead of print]

PMID:
31877445
3.

Silent symptoms of multiple sclerosis.

Lechner-Scott J, Waubant E, Levy M, Hawkes C.

Mult Scler Relat Disord. 2019 Nov;36:101453. doi: 10.1016/j.msard.2019.101453. Epub 2019 Oct 18. No abstract available.

PMID:
31812240
4.

The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review.

Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, van der Mei I, Berk M, Dean OM, Taylor B, Broadley S, Lechner-Scott J, Jacka FN, Lucas RM, Ponsonby AL; RELIEF Trial team.

Mult Scler Relat Disord. 2019 Nov 2;37:101486. doi: 10.1016/j.msard.2019.101486. [Epub ahead of print] Review.

PMID:
31707234
5.

Grassroot efforts towards diversity in MS care and research: Win-win for patients and science.

Waubant E, Levy M, Lechner-Scott J, Giovannoni G, Hawkes C.

Mult Scler Relat Disord. 2019 Oct;35:A1-A2. doi: 10.1016/j.msard.2019.101428. Epub 2019 Oct 2. No abstract available.

PMID:
31679745
6.

2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis.

Quadrelli S, Ribbons K, Arm J, Al-Iedani O, Lechner-Scott J, Lea R, Ramadan S.

Ther Adv Neurol Disord. 2019 Oct 19;12:1756286419877081. doi: 10.1177/1756286419877081. eCollection 2019.

7.

Multiple sclerosis and migration revisited.

Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Waubant E (Chief editors).

Mult Scler Relat Disord. 2019 Sep;34:A1-A2. doi: 10.1016/j.msard.2019.08.001. Epub 2019 Aug 1. No abstract available.

PMID:
31543261
8.

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, Pilli D, Patrick E, van der Walt A, Monif M, Tantsis EM, Yiu EM, Vucic S, Henderson APD, Fok A, Fraser CL, Lechner-Scott J, Reddel SW, Broadley S, Barnett MH, Brown DA, Lunemann JD, Dale RC, Brilot F; Australasian and New Zealand MOG Study Group.

Acta Neuropathol Commun. 2019 Sep 3;7(1):145. doi: 10.1186/s40478-019-0786-3.

9.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T.

Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.

PMID:
31397221
10.

Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M.

Mult Scler Relat Disord. 2019 Aug;33:A1-A2. doi: 10.1016/j.msard.2019.07.001. Epub 2019 Jul 2. No abstract available.

PMID:
31324299
11.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
12.

One size doesn't fit all.

Lechner-Scott J, Giovannoni G, Hawkes C, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Jun;31:A1-A2. doi: 10.1016/j.msard.2019.04.034. Epub 2019 Apr 30. No abstract available.

PMID:
31159999
13.

Three suggestions to decrease the financial burden of MS treatments.

Waubant E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M.

Mult Scler Relat Disord. 2019 May;30:A1. doi: 10.1016/j.msard.2019.03.023. No abstract available.

PMID:
30987755
14.

Evaluation of MS related central fatigue using MR neuroimaging methods: Scoping review.

Arm J, Ribbons K, Lechner-Scott J, Ramadan S.

J Neurol Sci. 2019 May 15;400:52-71. doi: 10.1016/j.jns.2019.03.007. Epub 2019 Mar 14. Review.

PMID:
30903860
15.

Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease.

Levy M, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Apr;29:A1-A2. doi: 10.1016/j.msard.2019.03.007. No abstract available. Erratum in: Mult Scler Relat Disord. 2019 Jul;32:138.

PMID:
30885376
16.

Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner?

Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Waubant E.

Mult Scler Relat Disord. 2019 Feb;28:A1-A2. doi: 10.1016/j.msard.2019.02.015. No abstract available.

PMID:
30823982
17.

Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity.

Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, Lechner-Scott J, Henderson A, Reddel S, Dale RC, Brilot F.

Eur J Neurol. 2019 Aug;26(8):1137-e75. doi: 10.1111/ene.13932. Epub 2019 Mar 5.

PMID:
30748058
18.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

19.

Should our treatment target in MS include the intrathecal plasma cell response?

Giovannoni G, Hawkes C, Levy M, Lechner-Scott J, Waubant E.

Mult Scler Relat Disord. 2019 Jan;27:A1-A2. doi: 10.1016/j.msard.2018.12.039. No abstract available.

PMID:
30642567
20.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
21.

Diurnal variability of cerebral metabolites in healthy human brain with 2D localized correlation spectroscopy (2D L-COSY).

Arm J, Al-Iedani O, Lea R, Lechner-Scott J, Ramadan S.

J Magn Reson Imaging. 2019 Aug;50(2):592-601. doi: 10.1002/jmri.26642. Epub 2019 Jan 10.

PMID:
30629765
22.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
23.

Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis?

Agland S, Lydon A, Shaw S, Lea R, Mortimer-Jones S, Lechner-Scott J.

Mult Scler J Exp Transl Clin. 2018 Nov 26;4(4):2055217318813179. doi: 10.1177/2055217318813179. eCollection 2018 Oct-Dec.

24.

Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients.

Maltby VE, Lea RA, Graves MC, Sanders KA, Benton MC, Tajouri L, Scott RJ, Lechner-Scott J.

Sci Rep. 2018 Nov 27;8(1):17418. doi: 10.1038/s41598-018-35603-0.

25.

Diurnal stability and long-term repeatability of neurometabolites using single voxel 1H magnetic resonance spectroscopy.

Al-Iedani O, Arm J, Ribbons K, Lea R, Lechner-Scott J, Ramadan S.

Eur J Radiol. 2018 Nov;108:107-113. doi: 10.1016/j.ejrad.2018.09.020. Epub 2018 Sep 17.

PMID:
30396641
26.

Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients.

Rhead B, Brorson IS, Berge T, Adams C, Quach H, Moen SM, Berg-Hansen P, Celius EG, Sangurdekar DP, Bronson PG, Lea RA, Burnard S, Maltby VE, Scott RJ, Lechner-Scott J, Harbo HF, Bos SD, Barcellos LF.

PLoS One. 2018 Oct 31;13(10):e0206511. doi: 10.1371/journal.pone.0206511. eCollection 2018.

27.

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.

Ahmad H, van der Mei I, Taylor BV, Lucas RM, Ponsonby AL, Lechner-Scott J, Dear K, Valery P, Clarke PM, Simpson S, Palmer AJ.

Mult Scler. 2019 Nov;25(13):1800-1808. doi: 10.1177/1352458518806103. Epub 2018 Oct 23.

PMID:
30351240
28.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
29.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
30.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
31.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

32.

DNA methylation changes in CD4+ T cells isolated from multiple sclerosis patients on dimethyl fumarate.

Maltby VE, Lea RA, Ribbons KA, Sanders KA, Kennedy D, Min M, Scott RJ, Lechner-Scott J.

Mult Scler J Exp Transl Clin. 2018 Jul 17;4(3):2055217318787826. doi: 10.1177/2055217318787826. eCollection 2018 Jul-Sep. Erratum in: Mult Scler J Exp Transl Clin. 2018 Oct 09;4(4):2055217318805576.

33.

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.

Groen K, Maltby VE, Lea RA, Sanders KA, Fink JL, Scott RJ, Tajouri L, Lechner-Scott J.

BMC Med Genomics. 2018 May 21;11(1):48. doi: 10.1186/s12920-018-0365-7.

34.

Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T.

Arm J, Al-Iedani O, Quadrelli S, Ribbons K, Lea R, Lechner-Scott J, Ramadan S.

J Magn Reson Imaging. 2018 Dec;48(6):1559-1569. doi: 10.1002/jmri.26036. Epub 2018 Apr 23.

PMID:
29684257
35.

Letter to the editor: blood processing and sample storage have negligible effects on methylation.

Groen K, Lea RA, Maltby VE, Scott RJ, Lechner-Scott J.

Clin Epigenetics. 2018 Feb 14;10:22. doi: 10.1186/s13148-018-0455-6. eCollection 2018.

36.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15.

37.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.

38.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
39.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: Mult Scler. 2017 Dec;23(14):NP1.

PMID:
28857680
40.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

41.

EBV and MS: Major cause, minor contribution or red-herring?

Burnard S, Lechner-Scott J, Scott RJ.

Mult Scler Relat Disord. 2017 Aug;16:24-30. doi: 10.1016/j.msard.2017.06.002. Epub 2017 Jun 10. Review.

PMID:
28755681
42.

Differential methylation at MHC in CD4+ T cells is associated with multiple sclerosis independently of HLA-DRB1.

Maltby VE, Lea RA, Sanders KA, White N, Benton MC, Scott RJ, Lechner-Scott J.

Clin Epigenetics. 2017 Jul 18;9:71. doi: 10.1186/s13148-017-0371-1. eCollection 2017.

44.

Erythrocytes in multiple sclerosis - forgotten contributors to the pathophysiology?

Groen K, Maltby VE, Sanders KA, Scott RJ, Tajouri L, Lechner-Scott J.

Mult Scler J Exp Transl Clin. 2016 May 19;2:2055217316649981. doi: 10.1177/2055217316649981. eCollection 2016 Jan-Dec. Review.

45.

Favourable Outcome in a 33-Year-Old Female with Acute Haemorrhagic Leukoencephalitis.

Solis WG, Waller SE, Harris AK, Sugo E, Hansen MA, Lechner-Scott J.

Case Rep Neurol. 2017 May 5;9(1):106-113. doi: 10.1159/000472706. eCollection 2017 Jan-Apr.

46.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

47.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
48.

Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.

Caruana P, Lemmert K, Ribbons K, Lea R, Lechner-Scott J.

Mult Scler. 2017 Oct;23(11):1479-1487. doi: 10.1177/1352458516679267. Epub 2016 Nov 14.

PMID:
28273762
49.

Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis.

Al-Iedani O, Lechner-Scott J, Ribbons K, Ramadan S.

J Biomed Sci. 2017 Feb 28;24(1):17. doi: 10.1186/s12929-017-0323-2. Review.

50.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331

Supplemental Content

Loading ...
Support Center